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INTRODUCTION
Aspirin has been known 
for more than a hundred years 
for its antiphlogistic and pain 
killer effects. Since its anti-
platelet activity was recognized 
in the late 1960s [1], aspirin 
has become one of the most 
used medication mainly for 
primary or secondary prevention 
of cardiovascular events and 
for its classical anti-analgesic 
properties against migraine, 
acute pain, osteoarthritis or 
SYSTEMATIC REVIEW AND META-ANALYSIS
ABSTRACT
Background & Aims: Aspirin is one of the most widely used medication for its analgesic and anti-platelet 
properties and thus a major cause for gastrointestinal (GI) bleeding. This study compared the preventive effect 
of histamine-2 receptor antagonists (H2RAs) and proton-pump inhibitors (PPIs) against chronic low-dose 
aspirin (LDA)-related GI bleeding and ulcer formation. 
Methods: Electronic databases of Pubmed, Embase and Cochrane Central Register of Controlled Trials were 
searched for human observations (randomised controlled trials and observational studies) comparing the 
long term effects of PPIs and H2RAs treatment in the prevention of GI bleeding or ulcer formation in patients 
on chronic LDA treatment listed up till September 30, 2016. Two independent authors searched databases 
using PICO questions (aspirin, H2RA, PPI, GI bleeding or ulcer), and reviewed abstracts and articles for 
comprehensive studies keeping adequate study quality. Data of weighted odds ratios were statistically evaluated 
using Comprehensive Metaanalysis (Biostat, Inc., Engelwood, MJ, USA), potential bias was checked.
Results: Nine studies for GI bleeding and eight studies for ulcer formation were found meeting inclusion 
criteria, altogether 1,879 patients were included into review. The H2RAs prevented less effectively LDA-
related GI bleeding (OR= 2.102, 95% CI: 1.008-4.385, p<0.048) and ulcer formation (OR= 2.257, 95% CI: 
1.277-3.989, p<0.005) than PPIs.
Conclusion: The meta-analysis showed that H2RAs were less effective in the prevention of LDA-related GI 
bleeding and ulcer formation suggesting the preferable usage of PPIs in case of tolerance.
Key words: Low-dose aspirin treatment – Proton pump inhibitors – Histamine receptor antagonists – 
Gastrointestinal bleeding – Ulcer – Aspirin-induced gastroenteropathy. 
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postoperative pain [2-6]. However, administration of aspirin 
increases the risk for gastrointestinal (GI) bleeding and ulcer 
formation [7, 8]. The dose of aspirin influences the occurrence 
of GI side effects, as well as the advanced age, a history of 
prior GI events, Helicobacter pylori (H. pylori) infection, 
concomitant clopidogrel, anti-coagulant, steroid or non-steroid 
anti-inflammatory drugs (NSAIDs) use, which further increase 
the bleeding risk [9-10]. Fortunately, aspirin used in low dose 
(LDA) (75-325 mg) still has beneficial effects in the prevention 
of vascular events with lesser frequency of aspirin-related GI 
side effects [11]. Aspirin induces mostly upper GI injury via 
inhibition of cyclooxygenase (COX) and cellular effects, acting 
by topical and systemic effects on epithelial and endothelial 
cells of mucosa resulting in lower rate of cell proliferation and 
migration [12-14]. Although aspirin inhibits cyclooxygenase-I 
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(COX-1) more potently than cyclooxygenase-II (COX-2), 
interestingly enteropathy occurs less frequently than in case of 
many other NSAIDs, which can be explained by the concept 
of Takeuchi et al. [15, 16]. According to their explanation, the 
inhibition of COX-1 will upregulate COX-2, and the produced 
prostaglandin E2 derived from COX-2 prevents the adverse 
effects mediated by COX-1 inhibition in the intestine resulting 
in less frequent enteropathy than in the case of both isoform 
inhibition [16].
Commonly used medication for reducing GI toxicity 
associated with prolonged use of aspirin includes prostaglandins, 
histamine-2 receptor antagonists (H2RAs), and proton 
pump inhibitors (PPIs) [17]. The prostaglandin E1 analogue 
misoprostol, the first agent approved for the prevention of 
NSAID-related ulceration, protects from ulcer formation and 
stimulates ulcer healing quite significantly. However, it has 
several side effects and disadvantages, most notably diarrhoea, 
dyspepsia and compliance problems related to q.i.d. dosage, 
all limiting its use [18, 19]. 
The H2RAs effectively prevent the development of 
gastric and duodenal ulcers as well as erosive esophagitis in 
patients chronically taking LDA, according to the FAMOUS 
(Famotidine for the Prevention of Peptic Ulcers in Users of 
Low-dose Aspirin) trial (OR: 0.2; 0.05; 0.20, respectively) [20]. 
Since PPIs inhibit acid secretion to a higher extent and result 
in faster ulcer healing, their prominent role in the prevention 
of aspirin or other NSAID-induced GI toxicity were concluded 
and resulted in their dominant use with such indications. 
However, the past two-decade long dominant use of PPIs has 
demonstrated certain disadvantages, namely side effects, such 
as a higher rate of infections, bone fractures, food allergy, 
development of fundic polyposis as well as an elevated risk of 
severe thromboembolism [21, 22]. The H2RAs are more cost-
effective and safer compared with PPIs. All these have led us 
to consider the use of H2RA again in certain anti-secretory 
indications, especially in the prevention of aspirin-induced GI 
bleeding in which the slightly lesser extent of acid inhibition 
might not result in its deficiency during long term use. Taha 
et al. confirmed that standard doses of famotidine decrease 
LDA-associated GI injuries and suggested that high-dose 
H2RAs are alternatives to PPIs in preventing LDA-associated 
GI bleeding [20]. It is still unclear if chronic H2RA intake is 
capable of preventing GI damage among patients taking aspirin 
for a longer period of time comparable to PPIs. 
This present study was aimed to evaluate whether H2RAs 
are being equal to PPIs in the prevention of LDA-related GI 
bleeding or ulcer formation.
METHODS
A systematic review of the studies was performed by the 
guidance of Preferred Reporting Items for Systematic Reviews 
and Meta-analysis (PRISMA) statement [23]. Inclusion criteria 
were the following: (1) Randomized controlled trials, case-
control and observational studies were included; (2) LDA-
taking, adult patients (≥18 years) were eligible for enrolment, 
if they had taken LDA for minimum of 2 weeks; (3) both H2RA 
takers and PPI takers should have been present as comparable 
experimental groups in the included studies; (4) the outcome 
of case numbers with bleeding and/or ulcer formation were 
mandatorily registered. According to the exclusion criteria, 
non-human studies, pharmacological experiments and case 
reports were foreclosed. Studies measuring Rockall scores for 
bleeding evaluation or Lanza scores for GI injury were not 
considered to be adequate for inclusion. 
The literature search of PubMed, Embase and Cochrane 
Central Register of Controlled Trials (CENTRAL) from 
their interception till September 30, 2016 were conducted. 
The filter of human studies was used. Studies published in 
the English language were selected. The combinations of the 
following terms were used for the literature search: aspirin, 
acetylsalicylic, proton pump inhibitor, PPI, esomeprazole, 
pantoprazole, omeprazole, rabeprazole, lansoprazole, 
histamine receptor antagonist, H2RA, famotidine, ranitidine, 
cimetidine, nizatidine, roxatidine, GI bleeding and ulcer (see 
Supplementary Table I). 
Two reviewers (I. S. and R. M.) screened the titles and 
abstracts of the studies for inclusion criteria. Studies not 
meeting the inclusion criteria or published in duplicate were 
eliminated from the analysis. Remaining studies were further 
analysed in full text. If differences were found in the reviewers’ 
judgement then a committee of five other researchers was 
invited to draw a conclusion. Data of articles enrolled were 
extracted by two independent researchers, and the number of 
patients in studied groups, number of patients with GI bleeding 
and ulcers, diagnostic method for bleeding and ulcer detection 
were summarized.
The risks of selection, detection, performance, attrition and 
reporting bias in the enrolled studies were also assessed by the 
two reviewers independently using the Cochrane Risk of Bias 
tool [24]. Low risk, high risk or unclear risk was determined 
in individual studies for (1) sequence generation, (2) allocation 
concealment, (3) blinding of participants and personnel, (4) 
blinding outcome assessment, (5) incompleteness outcome 
data, and (6) selective outcome reporting domains. Since 
not all domains in Cochrane Risk of Bias tool are relevant 
for non-RCT studies, we further examined the bias of 
observational studies for selection and information bias: (a) 
population selection, (b) assessment of exposure, (c) outcome 
interest, (d) case selection, (e) control selection, (f) matching 
and adjustment, (g) assessment of prognostic factors, (h) 
assessment of outcome, and (i) follow-up were judged [25-
27]. In case of disagreement in the reviewers’ assessment, a 
committee comprising five other researchers was invited to 
draw a conclusion.
The summarized data of bleeding and ulcer detected 
were expressed as odds ratio (OR) with 95% confidence 
interval (CI) for comparison. Between-study heterogeneity 
was tested with: (1) Q homogeneity test statistic (p values 
of less than 0.05 were considered as indicators of significant 
heterogeneity) and (2) I2 statistics, where I2 is the proportion 
of total variation attributable to between-study variability 
(an I2 value of more than 50 was considered as indicating 
considerable heterogeneity). These two values were used 
to model selection purposes too (fixed vs. random). The 
publication bias was tested by inspecting the Funnel plot. All 
analyses were performed using the software Comprehensive 
Metaanalysis (Biostat, Inc., Engelwood, MJ, USA). 
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RESULTS
The preliminary literature search identified 254 articles 
with available abstracts (Fig. 1). After subtracting duplications/
triplications (18/8), 214 articles were excluded after reading 
their title and abstract (174) or full text (46), due to exclusion 
criteria or to missing inclusion criteria. Six articles fulfilled all 
criteria [28-33]. One systematic review [34] checked during 
the assessment cited six additional Chinese papers fulfilling 
inclusion criteria and showed data suitable for comparison. The 
committee of reviewers accepted the inclusion of data derived 
from these Chinese written articles [35-40]. Altogether, nine 
articles reported bleeding, eight papers reported ulcer as an 
outcome, and five manuscripts investigated both bleeding and 
ulcer formation. All studies included were published between 
2007 and 2016. The characteristics of the studies included in 
this meta-analysis are summarized in Table I. The number of 
patients included in comparison groups ranged from 22 to 
163 (combined 962 in PPI treated group, 917 in H2RA treated 
group, altogether 1879 patients). One article did not state the 
anti-secretory medication doses. In the rest of the studies, the 
PPIs compared in the articles were pantoprazole, rabeprazole, 
esomeprazole, omeprazole and lansoprazole at doses from 
10 to 40 mg/day; and the H2RAs examined were famotidine 
and ranitidine 20-80 mg/day and 300 mg/day, respectively. 
The patients using concomitant medications or having other 
risk factors were not evaluated to represent mixed general 
population. 
Five RCT studies reported random sequence generation [30, 
31, 33, 38, 39]. Three articles stated allocation concealment; eight 
were unclear for this aspect of selection bias. Three blinded the 
participants and personnel, as well as the outcome assessment 
Table I. Summary of studies included in meta-analysis
Bleeding
Studies Study type Course Drug (dose) n Bleeding (%) Drug (dose) n Bleeding (%)
Lanas A et al. 2007 [28] Case-control 4y  PPI* 133 41 (31)  Ranitidine or 
Famotidine**
55 20 (36)
Hakimoto S et al. 2009 
[29]
Cohort 8-20m  PPI** – no 
details
150 2 (1.3)  H2R 
antagonists**
212 10 (4.7)
Ng FH et al. 2010 [30]  RCT 48w  Pantoprazole 
(20 mg bid)
65 0  (0)  Famotidine 
(40 mg bid)
65 5 (7.7)
Ng FH et al. 2012 [31]  RCT 4-52w  Esomeprazole 
(20 mg qd)
163 3 (1.8)  Famotidine 
(40 mg qd)
148 12 (8.1)
Yano et al. 2012 [32]  RCT 12m  Omeprazole 
(10 mg qd)
65 3 (4.6)  Famotidine 
(20 mg qd)
65 1 (1.5)
Sun EE et al. 2012 [35]  RCT 90d  Rabeprazole 
(20 mg qd)
40 0 (0)  Ranitidine 
(150 mg bid)
40 1 (2.5)
Wang YP et al. 2012 [36]  RCT 90d  Lansoprazole 
(30 mg qd)
23 0 (0)  Famotidine 
(20 mg qd)
22 1 (4.5)
Lu BJ et al. 2013 [37]  RCT 30d  Omeprazole 
(40 mg qd)
50 2 (4)  Ranitidine 
(150mg dq)
50 9 (18)
Chan et al. 2016 [33]  RCT 12m Rabeprazole 
(20mg qd)




Studies Study type Course Drug (dose) n Bleeding (%) Drug n Bleeding (%)
Guo M et al. 2009 [38]  RCT 90d  Omeprazole or 
Esomeprazole 
(20 mg qd)
42 6 (14.3)  Famotidine 
(20 mg bid)
22 5 (22.7)
Ng FH et al. 2010 [30]  RCT 48w  Pantoprazole 
(20 mg bid)
65 0 (0)  Famotidine 
(40 mg bid)
65 8 (12.3)
Ng FH et al. 2012 [31]  RCT 4-52w  Esomeprazole 
(20 mg qd)
163 1 (0.6)  Famotidine 
(40 mg qd)
148 6 (4.1)
Sun EE et al. 2012 [35]  RCT 90d  Rabeprazole 
(20 mg qd)
40 3 (7.5)  Ranitidine 
(150 mg bid)
40 11 (27.5)
Wang YP et al. 2012 [36]  RCT 90d  Lansoprazole 
(30 mg qd)
23 2 (8.7)  Famotidine 
(20 mg bid)
22 6 (27.3)
Wang J et al. 2012 [39]  RCT 90d  Esomeprazole 
(20 mg bid)
43 3 (7.0)  Famotidine 
(20 mg bid)
46 5 (10.9)
Hu L et al. 2013 [40]  RCT 90d  Rabeprazole 
(10 mg qd)
50 5 (10)  Famotidine 
(20mg bid)
50 9 (18)
Chan et al. 2016 [33]  RCT 12m Rabeprazole 
(20mg qd)
138 8 (0.5)  Famotidine 
(40 mg qd)
132 9 (0.1)
* All PPs (omeprazole, pantoprazole, esomeprazole, rabeprazole, lansoprazole) in all doses;  ** No dosage given;  *** No details given on types 
or doses.
398 Szabó et al
J Gastrointestin Liver Dis, December 2017 Vol. 26 No 4: 395-402
process [30, 31, 33]. Seven studies did not perform or state the 
performance of blinding on either side. Six studies were unclear 
for incomplete outcome data, while six studies were low risk for 
this aspect of attrition bias. All studies were judged low risk for 
reporting bias. The risk of bias within the twelve studies included 
in the meta-analysis is summarized in Fig. 2. 
Two non-RCT studies were further examined for bias 
relevant in cohort and case-control studies [25-27]. Both 
studies achieved mostly low risk for selection bias aspects. 
Study of Lanas et al. was judged low risk for matching and 
adjustment as well as assessment for prognostic factors and 
outcome. Risk of bias within two observational studies included 
in the meta-analysis is summarized in a combined table (Fig. 3).
We found the combined OR of 2.102 (95% CI: 1.008-4.385) 
for bleeding in H2RA treated group compared to PPI treated 
(Fig. 3). The OR for upper GI ulcer formation was 2.257 
(95% CI: 1.277-3.989) in H2RA treatment compared to PPI 
treatment (Fig. 4). The difference of risk for both GI bleeding 
and ulcer formation was significant (p<0.048; p<0.005, 
respectively). The visual analysis of Funnel plots did not reflect 
worthwhile publication bias. 
To further analyse the data quality, we compared the results 
of the RCT studies with the exclusion of non-RCT studies. 
The OR of RCT studies for upper GI bleeding was 2.553 
(95% CI: 1.187-5.489) in H2RA treatment compared to PPI 
treatment (p<0.016). Since the studies used for the analysis of 
ulcer formation included only RCTs no further analyses were 
performed for the investigation of ulcer formation from this 
aspect. Visual observation of Funnel plot of RCT studies for 
ulcer bleeding showed acceptable spread of data. 
DISCUSSION
It is well known that aspirin treatment causes GI side 
effects, such as dyspepsia, GI damage and bleeding [7, 8]. A 
recent meta-analysis of the RCT data showed that LDA use 
was associated with a 50% increase in UGIB risk (OR 1.5 [95% 
CI 1.2 to 1.8]). Upper GI bleeding risk was most pronounced 
in observational studies (OR 3.1, 95% CI 2.5 to 3.7) [41]. Very 
Fig. 1. Flow-chart of study selection and inclusion
Fig. 2. Summary of risk of bias of studies included in meta-analysis
Fig. 3. Summary of risk of bias of non-RCT studies included in 
meta-analysis
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Fig. 4. Forest plot analysis of studies of H2RA and PPI for the prevention of low dose aspirin-induced 
gastrointestinal bleeding (Q value: 8.585; df(Q): 9; P-value: 0.284; I2:18.46%).
Fig. 5. Forest plot analysis of studies of H2RA and PPI for the prevention of low dose aspirin-
induced upper gastrointestinal ulcer formation (Q value: 12.936; df(Q): 8; P-value: 0,114; I2: 
38.16%).
often the absence of aspirin-induced patients’ complaints does 
not reflect GI damage and ongoing bleeding [42]. Which might 
be the reason why a lot of chronic aspirin takers do not use 
concomitant GI protective drugs. Observational studies still 
reflect that less than 50% of the aspirin users take protective 
maintenance therapy [43]. Since more and more patients take 
aspirin worldwide for primary and secondary prevention of 
cardiovascular disease, to promote physicians’ poor awareness 
toward the prevention of GI damage is an important task. Anti-
secretory medications are effective in reducing GI complications 
of aspirin [44]. The PPIs being potent inhibitors of gastric acid 
secretion have been extensively studied in preventing aspirin-
induced GI complications. Recently, we are facing the side 
effects of long-term PPI therapy, such as Clostridium difficile 
colitis, community-acquired pneumonia, osteoporosis, iron and 
vitamin deficiencies, as well as the increase of food allergies [45-
49]. The interaction caused by PPIs on the cytochrome enzymes 
hazard appropriate drug actions of clopidogrel, vitamin K 
antagonists, and benzodiazepines [50, 51]. All these raised 
the question whether the less expensive H2RAs are suitable to 
prevent aspirin-induced GI bleeding. The only meta-analysis 
published so far [34] comparing H2RAs to PPI in the prevention 
of ASA-related GI harms examined exclusively RCT studies 
up till 2013. In the present study we extended the review to a 
wider field including data of appropriate observational studies 
and more recent findings of literature. 
Our meta-analysis containing data of 12 studies showed 
that H2RAs are less effective in preventing upper GI ulcers and 
bleeding in LDA takers. However, these studies were mainly 
conducted in far eastern countries (China, Japan), and their 
sample numbers were also small. The gastric acid secretion 
of far-east patients, especially in Japan has been shown to be 
lower than in western developed countries probably due to 
higher H. pylori infection prevalence [52]. Extrapolating from 
our results, probably the difference in the preventive action of 
PPIs and H2RAs might be larger in European and American 
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population. Analysing the risk of bias within the included 
studies, we found that uncertain risks of bias were relatively 
frequent among the examined aspects, suggesting the rather 
low quality of the included studies. Studies with a lower rate of 
uncertainty in bias showed a higher difference in GI bleeding 
and ulcer formation rate between H2RA and PPI groups, also 
suggesting the relevance of our results. 
Beside the small sample number and the relatively high 
partition of low quality of studies, this study has another 
limitation. We did not divide the patients into subgroups 
by their risk factors for GI bleeding such as age, history 
of previous bleeding, H. pylori positivity, and concomitant 
medications due to lack of data. Our goal was to represent 
a heterogeneous general population, and to predict whether 
H2RAs are suitable to substitute PPIs in the prevention of 
LDA-induced GI bleeding and ulcer formation without 
further examination of patients. It is still possible that 
subgroups of patients lacking certain risk factor(s) might 
qualify for prevention achieved by H2RAs along with long-
term aspirin treatment. Since the dose range of LDA is wide 
(75-325mg), the preventive efficacy against the lower range 
doses surely differs from the top dose, which may point out 
the possibility for H2RAs in the protection against low range 
LDA-caused GI damage. This rationale is supported by the 
data of Lanas et al. [28] showing the adjusted relative risk 
(RR) for peptic ulcer bleeding according to aspirin doses. He 
found that at 100 mg aspirin use, the relative risk (RR) for 
peptic ulcer bleeding is almost the same in PPI takers and 
H2RA takers (0.32 and 0.33, respectively), whereas it differs 
quite a bit in 300 or 500 mg aspirin users (RR: 0,32, 0.44; and 
0.19, 0.49, respectively). Genetic differences may also lead to 
different susceptibility for damage. Possibly, future findings on 
genetic polymorphisms of cyclooxygenases, factors involved 
in platelet aggregation or enzymes in aspirin metabolism will 
further help in the fight against aspirin-induced mucosal 
damage.
CONCLUSION
The PPIs are superior to the H2RAs in preventing LDA-
associated GI ulcer formation and bleeding. Further high 
quality studies on risk factors-related differences on the 
efficacy of preventive actions of PPIs and H2RAs might reveal 
new details and result in rewarding forthcoming therapeutic 
protocols. 
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